156 related articles for article (PubMed ID: 17300833)
1. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
2. Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Thomas H
Anticancer Res; 2007; 27(1A):273-8. PubMed ID: 17352243
[TBL] [Abstract][Full Text] [Related]
3. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
Appleyard MV; O'Neill MA; Murray KE; Paulin FE; Bray SE; Kernohan NM; Levison DA; Lane DP; Thompson AM
Int J Cancer; 2009 Jan; 124(2):465-72. PubMed ID: 19003963
[TBL] [Abstract][Full Text] [Related]
4. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
5. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
6. Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study.
Kolodziej M; Goetz C; Di Fazio P; Montalbano R; Ocker M; Strik H; Quint K
Oncol Rep; 2015 Sep; 34(3):1549-56. PubMed ID: 26151768
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
8. Seliciclib in malignancies.
Aldoss IT; Tashi T; Ganti AK
Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
[TBL] [Abstract][Full Text] [Related]
9. Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis.
Sheryanna AM; Smith J; Bhangal G; Barnett A; McClue S; Tam FW; Cook T; Pusey CD
Nephrology (Carlton); 2011 May; 16(4):410-6. PubMed ID: 21518118
[TBL] [Abstract][Full Text] [Related]
10. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
11. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
[TBL] [Abstract][Full Text] [Related]
12. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
[TBL] [Abstract][Full Text] [Related]
13. A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
Ong PS; Wang L; Chia DM; Seah JY; Kong LR; Thuya WL; Chinnathambi A; Lau JY; Wong AL; Yong WP; Yang D; Ho PC; Sethi G; Goh BC
Cancer Lett; 2016 Oct; 381(1):49-57. PubMed ID: 27461583
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
Liang YC; Lin-Shiau SY; Chen CF; Lin JK
J Cell Biochem; 1999 Oct; 75(1):1-12. PubMed ID: 10462699
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.
Hui AB; Yue S; Shi W; Alajez NM; Ito E; Green SR; Frame S; O'Sullivan B; Liu FF
Clin Cancer Res; 2009 Jun; 15(11):3716-24. PubMed ID: 19470731
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F
Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859
[TBL] [Abstract][Full Text] [Related]
17. Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms.
Yeh CC; Fan Y; Jiang L; Yang YL; He B; You L; Mann M
Anticancer Res; 2015 Jun; 35(6):3167-73. PubMed ID: 26026076
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
20. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
Galimberti F; Thompson SL; Liu X; Li H; Memoli V; Green SR; DiRenzo J; Greninger P; Sharma SV; Settleman J; Compton DA; Dmitrovsky E
Clin Cancer Res; 2010 Jan; 16(1):109-20. PubMed ID: 20028770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
